Cost-effectiveness analysis of rezvilutamide versus bicalutamide in the treatment of metastatic hormone-sensitive prostate cancer.
Haiying DingShujing LiXinglu XuWeiben XuChaoneng HeWen-Xiu XinZha-Jun ZhanLuo FangPublished in: BMJ open (2024)
Rezvilutamide in combination with ADT is more cost-effective compared with bicalutamide plus ADT as the first-line treatment of mHSPC from the perspective of the Chinese healthcare system.